ILIAS Biologics
June 24, 2026
Theater 1
Type: Company Presentation
Focus Area:
Platform for Therapeutics
ILIAS Biologics is a clinical-stage biotechnology company developing engineered exosome therapeutics for targeted intracellular delivery. Leveraging its proprietary EXPLOR® platform, ILIAS enables efficient loading and delivery of functional proteins, including transcription factors and intracellular antibodies, into exosomes to modulate disease-driving pathways.
The company’s lead asset, ILB-202, delivers a super-repressor IκB (srIκB) to inhibit NF-κB signaling and has completed Phase 1 clinical trials, demonstrating favorable safety and tolerability. ILIAS is advancing a diverse pipeline across inflammation-driven indications, including renal, CNS, autoimmune, ophthalmic, and women’s health diseases, and is expanding its platform through targeted exosome engineering technologies (Exo-Target®). The company seeks global partnerships to accelerate clinical development and broaden therapeutic applications.
Company HQ City:
Yuseong-gu
Company HQ State:
Daejeon
Company HQ Country:
Korea, Republic of
Year Founded:
2015
Lead Product in Development:
ILB-202
CEO
Chulhee Choi, MD, PhD.
Development Phase of Lead Product
Phase I
When you expect your next catalyst update?
December 2026
What is your next catalyst (value inflection) update?
IND approval for a Phase 1b/2a clinical trial of ILB-202, enabling advancement into patient-based efficacy studies.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}